Articles scientifiques

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. (published online 11/2012)

Auteurs : Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V, Hayes DF, Piccart-Gebhart M, Pierga JY
Année : 2013
Journal : Cancer Metastasis Rev
Volume : 32(1-2
Pages : 179-88

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.

Auteurs : Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M
Année : 2013
Journal : Breast Cancer Res. Treat.
Volume : 139(1)
Pages : 13-22

Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Auteurs : Peccatori FA, Azim HA, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, Pentheroudakis G
Année : 2013
Journal : Ann Oncol
Volume : 24 Suppl 6
Pages : vi160-70

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.(epub nov 2013)

Auteurs : Awada A, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart-Gebhart M, Schöffski P
Année : 2013
Journal : Invest New Drugs
Volume : 31(3)
Pages : 734-41

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

Auteurs : Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart M
Année : 2013
Journal : Cancer Treat Rev
Volume : 39(8)
Pages : 935-46

Breast cancer arising at a young age: Do we need to define a cut-off?

Auteurs : Azim HA, Azim H
Année : 2013
Journal : Breast
Volume : 22(6)
Pages : 1007-8

Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy.

Auteurs : Maisonobe JA, Garcia C, Necib H, Vanderlinden B, Hendlisz A, Flamen P, Buvat I
Année : 2013
Journal : Eur J Nucl Med Mol Imaging
Volume : 40(2)
Pages : 166-74

Supportive care in cancer patients: a unifying concept.

Auteurs : Klastersky J
Année : 2013
Journal : Curr Opin Oncol
Volume : 25(4)
Pages : 341

Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial.

Auteurs : Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber Rd, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M
Année : 2013
Journal : J. Clin. Oncol.
Volume : 31(16)
Pages : 1954-60

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Auteurs : Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
Année : 2013
Journal : Breast Cancer Res
Volume : 15(5)
Pages : R86

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Auteurs : Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A
Année : 2013
Journal : Future Oncol
Volume : 9(10)
Pages : 1477-87

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.

Auteurs : Von Minckwitz G, Martin M, Wilson G, Alba E, Schmidt M, Biganzoli L, Awada A
Année : 2013
Journal : Crit Rev Oncol Hematol
Volume : 85(3)
Pages : 315-31

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Auteurs : Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Borbath I, Dresse D, Houbier G, Fried M, Awada A, Piccart-Gebhart M, Laethem JL, Flamen P
Année : 2013
Journal : BMC Cancer
Volume : 13(1)
Pages : 190

Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.

Auteurs : Zardavas D, Bozovic-Spasojevic I, de Azambuja E
Année : 2012
Journal : Curr Opin Oncol
Volume : 24(6)
Pages : 612-22

Technological innovation and healthcare professionals' workloads: an ambiguous relationship.

Auteurs : de Pires DE, Bertoncini JH, Trindade Lde L, Matos E, de Azambuja E, Borges AM
Année : 2012
Journal : Rev Gaucha Enferm
Volume : 33(1)
Pages : 157-68

Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: At the crossroad?

Auteurs : Gombos A, Metzger-Filho O, Dal Lago L, Awada A
Année : 2012
Journal : Invest New Drugs
Volume : 30(6)
Pages : 2433-42

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Auteurs : Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T
Année : 2012
Journal : Eur. J. Cancer
Volume : 48(4)
Pages : 465-74

Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial.

Auteurs : Piccart-Gebhart M
Année : 2012
Journal : Ann Oncol
Volume : 23 Suppl 6
Pages : vi5-vi6

Second primary cancers in head and neck cancer patients: a challenging entity.

Auteurs : de Castro G, Awada A
Année : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pages : 203-4

Thérapies biologiques ciblées et cancer thyroïdien récidivant : enfin un standard thérapeutique ?

Auteurs : Lalami Y
Année : 2012
Journal : Onco-Hémato
Volume : 6(5)
Pages : 45-51